ProSavin
ProSavin
ProSavin (/proʊˈseɪvɪn/) is a gene therapy treatment developed for Parkinson's disease. It is designed to deliver three dopamine-synthesizing genes directly to the striatum region of the brain, which is responsible for movement control.
Etymology
The term "ProSavin" is a combination of "pro" (from the Greek πρό, meaning "before") and "savin" (from the Latin "salvare", meaning "to save"). The name reflects the therapy's aim to prevent or slow the progression of Parkinson's disease.
Mechanism of Action
ProSavin works by using a lentivirus vector to deliver three genes - tyrosine hydroxylase (TH), cyclohydrolase 1 (CH1), and aromatic L-amino acid decarboxylase (AADC) - to the striatum. These genes are involved in the synthesis of dopamine, a neurotransmitter that is deficient in Parkinson's disease. By increasing dopamine production, ProSavin aims to alleviate the symptoms of Parkinson's disease.
Clinical Trials
ProSavin has undergone Phase I/II clinical trials to assess its safety and efficacy. The results have shown that the treatment is well-tolerated and can lead to significant improvements in motor function in patients with advanced Parkinson's disease.
Related Terms
- Gene therapy
- Parkinson's disease
- Dopamine
- Striatum
- Lentivirus
- Tyrosine hydroxylase
- Cyclohydrolase 1
- Aromatic L-amino acid decarboxylase
- Phase I/II clinical trials
External links
- Medical encyclopedia article on ProSavin
- Wikipedia's article - ProSavin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski